JNJ-27141491

JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2[1].

Product Specifications

CAS Number

[871313-59-6]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jnj-27141491.html

Purity

97.01

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC[C@@H](C1=CC(F)=C(F)C=C1)N2C(C(OC)=O)=C(C3=CC=NO3)NC2=S

Molecular Formula

C17H15F2N3O3S

Molecular Weight

379.38

Precautions

H315, H319

References & Citations

[1]Buntinx M, et al. Pharmacological profile of JNJ-27141491 [ (S) -3-[3,4-difluorophenyl) -propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther. 2008 Oct;327 (1) :1-9.